Molecular target
PCSK9 (Proprotein Convertase Subtilisin/Kexin 9)
Hepatically-secreted protein that targets the LDL receptor for degradation. Inhibition (alirocumab, evolocumab — monoclonal antibodies; inclisiran — siRNA) preserves LDL receptors, dramatically lowering serum LDL by 50-60%. Among the most efficacious lipid-lowering interventions ever developed.
Educational use only. This page summarizes published research and traditional-use records for educational purposes. It does not diagnose, treat, cure, or prevent any disease. Do not start, stop, or change medications based on this information. Discuss any decisions about therapies — pharmaceutical or botanical — with a qualified clinician who knows your medical history.
No PHI / HIPAA notice: Do not share Protected Health Information (PHI) of any patient on this site — including names, dates of birth, addresses, MRNs, or any identifying information. Use abstract case framing only. Sharing PHI with non-covered entities risks HIPAA violation regardless of platform capability.
Pharmaceutical agents
Drugs that act on PCSK9 (Proprotein Convertase Subtilisin/Kexin 9)
These medications have PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) among their molecular targets. Sharing a target is a mechanistic relationship — it does not make any plant below an alternative to, or substitute for, these drugs.